Q-Med obtains approval for MACROLANETM VRF in Europe

Q-Med obtains approval for MACROLANETM VRF in Europe

MACROLANE VRF is a natural gel that is injected into the skin. The product is
based on Q-Med's patented technology, NASHA, for the production of stabilized,  
non-animal hyaluronic acid. MACROLANE VRF can be used in body contouring both to
give volume and to smooth out irregularities all over the body.

“Now there is a product that in a naturally way may recreate the body shapes
that have been lost as a consequence of aging. MACROLANE VRF may refine and
shape breast, decolletage, buttocks and other parts of the body according to the
individual consumer's needs. Q-Med has conducted research and development for
quite some time in this area and we feel very proud today” says Bengt Ågerup,
CEO, Q-Med AB.

The first of Q-Med's products based on NASHA, RESTYLANE, was approved in Europe
in 1996 and since then seven million treatments have been performed. MACROLANE
VRF will be launched for plastic surgeons during 2007 and 2008.


Queries should be addressed to: 
Bengt Ågerup, CEO
Tel: +46 (0)70 974 9025
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70 974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.